Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan

Introduction: Kras mutation is the most common driver oncogene present in patients with NSCLC. Recently, the precision medicine for patients with Kras-mutated NSCLC has been under investigation, but the best treatment is still unknown. This study aimed to analyze the clinical characteristics, immune...

Full description

Bibliographic Details
Main Authors:	Shang-Gin Wu, MD, PhD, Wei-Yu Liao, MD, PhD, Kang-Yi Su, PhD, Sung-Liang Yu, PhD, Yen-Lin Huang, MD, Chong-Jen Yu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jin-Yuan Shih, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2021-02-01
Series:	JTO Clinical and Research Reports
Subjects:	Kras mutation G12C Lung cancer Immunotherapy PD-L1 Concomitant mutation
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364320301910

Similar Items

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01)

Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLC
by: Jacqueline V. Aredo, MD, MS, et al.
Published: (2024-12-01)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
by: Anne-Marie Ruppert, MD, PhD, et al.
Published: (2020-09-01)

Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study
by: Hirotsugu Kenmotsu, MD, PhD, et al.
Published: (2024-11-01)

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
by: Vincent D. de Jager, MD, et al.
Published: (2024-12-01)

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature
by: Shannon S. Zhang, MD, et al.
Published: (2022-09-01)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
by: Jean-Louis Pujol, MD, PhD, et al.
Published: (2021-11-01)

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC
by: Alissa J. Cooper, MD, et al.
Published: (2022-09-01)

Rapid Response to Sotorasib of a Patient With KRAS G12C-Mutated Lung Cancer With Cancer-Associated Disseminated Intravascular Coagulation: A Case Report
by: Kei Kunimasa, MD, PhD, et al.
Published: (2023-01-01)

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report
by: Masafumi Saiki, MD, et al.
Published: (2024-01-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
by: Anneloes L. Noordhof, MD, et al.
Published: (2023-09-01)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
by: Kathryn C. Arbour, MD, et al.
Published: (2022-01-01)

Long-Term Recurrence of Completely Resected NSCLC
by: Katsuhiro Masago, MD, PhD, et al.
Published: (2020-09-01)

Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)
by: Jiyun Lee, MD, et al.
Published: (2022-01-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
by: Daichi Fujimoto, MD, et al.
Published: (2022-02-01)

Superimposition of checkerboard distribution of ephelides and neurofibromas in a patient with segmental neurofibromatosis
by: Hisato Iriki, MD, PhD, et al.
Published: (2022-07-01)

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01)

A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
by: Kenji Morimoto, MD, PhD, et al.
Published: (2022-09-01)

Afatinib and Necitumumab in EGFR-Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors
by: Nathaniel J. Myall, MD, et al.
Published: (2025-02-01)

Evaluation of KRAS Concomitant Mutations in Advanced Lung Adenocarcinoma Patients
by: Veronica Aran, et al.
Published: (2021-09-01)

Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
by: Yuto Terashima, MD, et al.
Published: (2023-11-01)

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy
by: Junko Tanizaki, MD, PhD, et al.
Published: (2023-12-01)

TP53 Loss of Heterozygosity Induces De Novo SCLC Formation in EGFR-Mutated Lung Adenocarcinoma: A Case Report
by: Kei Kunimasa, MD, PhD, et al.
Published: (2022-05-01)

Patients With BRAF-Mutant NSCLC May Not Benefit From Immune Checkpoint Inhibitors: A Population-Based Study
by: Chenxing Zhang, PhD, et al.
Published: (2020-03-01)

Brief Report: circRUNX1 as Potential Biomarker for Cancer Recurrence in EGFR Mutation-Positive Surgically Resected NSCLC
by: Carlos Pedraz-Valdunciel, PhD, et al.
Published: (2023-12-01)

Brief Report: A Blood-Based MicroRNA Complementary Diagnostic Predicts Immunotherapy Efficacy in Advanced-Stage NSCLC With High Programmed Death-Ligand 1 Expression
by: Timothy Rajakumar, MD, PhD, et al.
Published: (2022-08-01)

EGFR-Mutated Lung Adenocarcinoma With Li–Fraumeni Syndrome: The Imperative for Germline Testing in Patients With a Family History, a Case Report
by: Hiroyuki Fujii, MD, et al.
Published: (2025-02-01)

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC
by: Hitomi Jo, MD, PhD, et al.
Published: (2023-04-01)

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study
by: Yuki Katayama, MD, PhD, et al.
Published: (2024-03-01)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
by: Parvin Begum, MBChB.(Hons), et al.
Published: (2021-09-01)

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma
by: Yuji Uehara, MD, et al.
Published: (2025-03-01)

Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC
by: Edward S. Kim, MD, et al.
Published: (2022-01-01)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
by: Takanori Ito, MD, et al.
Published: (2023-05-01)

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060
by: Takehiro Tozuka, MD, et al.
Published: (2024-04-01)

Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC Harboring BRAF, MET, or HER2 Alterations
by: Marina C. Garassino, MD, et al.
Published: (2023-10-01)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
by: Marina C. Garassino, MD, et al.
Published: (2023-01-01)

Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC
by: Ezgi B. Ulas, BSc, et al.
Published: (2023-09-01)

Personalized Therapy in a Patient With EGFR-Mutated NSCLC Developing Sequential CCDC6-RET Fusion and BRAF V600E Mutation as Bypass Resistance Mechanisms
by: Arianna Marinello, MD, et al.
Published: (2025-03-01)

Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
by: Chee Khoon Lee, PhD, et al.
Published: (2025-02-01)